Maria C Schneeweiss1, Richard Wyss, Kristyn Chin, Joseph F Merola, Jonathan I Silverberg, Arash Mostaghimi, Sebastian Schneeweiss. 1. From the Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's, Harvard Medical School Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, MA Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC.
Abstract
BACKGROUND: Dupilumab-associated conjunctivitis in patients with atopic dermatitis (AD) is not fully characterized. OBJECTIVE: The aim of the study was to characterize the incidence of bacterial and nonbacterial conjunctivitis among patients with AD who initiated dupilumab. METHODS: Pooling longitudinal claims data from 2 US databases, we identified AD patients who newly filled either dupilumab or methotrexate, mycophenolate or cyclosporine, between March 2017 and January 2020. Outcomes were conjunctivitis and its subtypes, bacterial, allergic, and keratoconjunctivitis. Patient follow-up lasted 6 months and 1:1 propensity score (PS) matching-controlled confounding. RESULTS: Within 6 months of treatment initiation, the incidence of conjunctivitis was 6.6% in 3744 dupilumab initiators; bacterial conjunctivitis, 1.5%; allergic conjunctivitis, 2.2%; keratoconjunctivitis, 0.8%; and conjunctivitis requiring ophthalmic medication, 2.7%. After PS matching, dupilumab doubled the risk of conjunctivitis compared with methotrexate (relative risk [RR] 2.12; 1.56-2.91), mycophenolate (RR = 2.43; 1.32-4.47), or cyclosporine (RR = 1.83; 1.05-3.20). Risk of bacterial conjunctivitis was 1.6- to 4.0-fold increased with wide confidence intervals, and allergic conjunctivitis was increased 2.7- to 7-fold. There was no increased risk of keratoconjunctivitis. Patients with comorbid asthma had a further increased risk of conjunctivitis. CONCLUSIONS: One in 15 patients treated with dupilumab developed conjunctivitis driven by bacterial and allergic conjunctivitis and not keratoconjunctivitis. This risk was further increased with comorbid asthma.
BACKGROUND: Dupilumab-associated conjunctivitis in patients with atopic dermatitis (AD) is not fully characterized. OBJECTIVE: The aim of the study was to characterize the incidence of bacterial and nonbacterial conjunctivitis among patients with AD who initiated dupilumab. METHODS: Pooling longitudinal claims data from 2 US databases, we identified AD patients who newly filled either dupilumab or methotrexate, mycophenolate or cyclosporine, between March 2017 and January 2020. Outcomes were conjunctivitis and its subtypes, bacterial, allergic, and keratoconjunctivitis. Patient follow-up lasted 6 months and 1:1 propensity score (PS) matching-controlled confounding. RESULTS: Within 6 months of treatment initiation, the incidence of conjunctivitis was 6.6% in 3744 dupilumab initiators; bacterial conjunctivitis, 1.5%; allergic conjunctivitis, 2.2%; keratoconjunctivitis, 0.8%; and conjunctivitis requiring ophthalmic medication, 2.7%. After PS matching, dupilumab doubled the risk of conjunctivitis compared with methotrexate (relative risk [RR] 2.12; 1.56-2.91), mycophenolate (RR = 2.43; 1.32-4.47), or cyclosporine (RR = 1.83; 1.05-3.20). Risk of bacterial conjunctivitis was 1.6- to 4.0-fold increased with wide confidence intervals, and allergic conjunctivitis was increased 2.7- to 7-fold. There was no increased risk of keratoconjunctivitis. Patients with comorbid asthma had a further increased risk of conjunctivitis. CONCLUSIONS: One in 15 patients treated with dupilumab developed conjunctivitis driven by bacterial and allergic conjunctivitis and not keratoconjunctivitis. This risk was further increased with comorbid asthma.
Authors: Sebastian Schneeweiss; Amanda R Patrick; Til Stürmer; M Alan Brookhart; Jerry Avorn; Malcolm Maclure; Kenneth J Rothman; Robert J Glynn Journal: Med Care Date: 2007-10 Impact factor: 2.983
Authors: Jessica M Franklin; Jeremy A Rassen; Diana Ackermann; Dorothee B Bartels; Sebastian Schneeweiss Journal: Stat Med Date: 2013-12-09 Impact factor: 2.373
Authors: Andrew Blauvelt; Marjolein de Bruin-Weller; Melinda Gooderham; Jennifer C Cather; Jamie Weisman; David Pariser; Eric L Simpson; Kim A Papp; H Chih-Ho Hong; Diana Rubel; Peter Foley; Errol Prens; Christopher E M Griffiths; Takafumi Etoh; Pedro Herranz Pinto; Ramon M Pujol; Jacek C Szepietowski; Karel Ettler; Lajos Kemény; Xiaoping Zhu; Bolanle Akinlade; Thomas Hultsch; Vera Mastey; Abhijit Gadkari; Laurent Eckert; Nikhil Amin; Neil M H Graham; Gianluca Pirozzi; Neil Stahl; George D Yancopoulos; Brad Shumel Journal: Lancet Date: 2017-05-04 Impact factor: 79.321
Authors: Eric S Johnson; Barbara A Bartman; Becky A Briesacher; Neil S Fleming; Tobias Gerhard; Cynthia J Kornegay; Parivash Nourjah; Brian Sauer; Glen T Schumock; Art Sedrakyan; Til Stürmer; Suzanne L West; Sebastian Schneeweiss Journal: Pharmacoepidemiol Drug Saf Date: 2012-10-01 Impact factor: 2.890
Authors: Jeremy A Rassen; Abhi A Shelat; Jessica Myers; Robert J Glynn; Kenneth J Rothman; Sebastian Schneeweiss Journal: Pharmacoepidemiol Drug Saf Date: 2012-05 Impact factor: 2.890